We provide targeted DNA sequencing allowing us to focus specific areas of interest at a reduced price and faster delivery time. Our laboratory’s technology can accommodate small blood sample sizes, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.
NEXT GENERATION SEQUENCING – GERMLINE MUTATION
Our Cancer Sequencing Panel targets 94 genes and 284 SNPs that have been previously linked to a predisposition to common and rare forms of cancer such as leukemia, osteosarcoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, and skin cancer. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.
The test is intended to identify the variants that are associated with cancer. It is performed as a pre-symptomatic genetic test in order to determine whether persons with a family history of a cancer, but no current symptoms, has gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to gain evidence to confirm variants of association to cancer.
All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing Next Generation Sequencing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.